Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD.

Ann Oncol. 2019 Mar 7. pii: mdz077. doi: 10.1093/annonc/mdz077. [Epub ahead of print]

PMID:
30847464
2.

Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M.

J Thorac Oncol. 2019 Mar 1. pii: S1556-0864(19)30152-2. doi: 10.1016/j.jtho.2018.12.038. [Epub ahead of print]

PMID:
30831205
3.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
4.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. [Epub ahead of print]

PMID:
30496436
5.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
6.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
7.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
8.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

PMID:
30045933
9.

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.

Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT.

ESMO Open. 2018 Jul 12;3(5):e000364. doi: 10.1136/esmoopen-2018-000364. eCollection 2018.

10.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

PMID:
30017832
11.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.

PMID:
30006423
12.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

13.

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.

J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20.

PMID:
29935304
14.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

15.

Type A thymoma presenting with bone metastasis.

Montecalvo J, Chang J, Rekhtman N, Antonescu CR, Bains MS, Fabbri N, Plodkowski AJ, Riely GJ, Travis WD, Sauter JL.

Histopathology. 2018 Oct;73(4):701-703. doi: 10.1111/his.13662. Epub 2018 Jul 8. No abstract available.

PMID:
29855070
16.

Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.

Arbour KC, Riely GJ.

Cancer. 2018 Jun 1;124(11):2272-2275. doi: 10.1002/cncr.31289. Epub 2018 Apr 12. No abstract available.

PMID:
29645085
17.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

PMID:
29610121
18.

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M.

Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12.

PMID:
29530932
19.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.

20.

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.

Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ.

Clin Cancer Res. 2018 Jan 15;24(2):334-340. doi: 10.1158/1078-0432.CCR-17-1841. Epub 2017 Oct 31.

21.

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Smith TJ, Hanna N, Johnson D, Baker S Jr, Biermann WA, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Tashbar J, Temin S, Masters G.

J Oncol Pract. 2017 Dec;13(12):780-783. doi: 10.1200/JOP.2017.027367. Epub 2017 Oct 5. No abstract available.

PMID:
28981389
22.

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.

Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA.

Cancer. 2018 Jan 1;124(1):105-109. doi: 10.1002/cncr.30990. Epub 2017 Sep 21.

23.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

24.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G.

J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.

PMID:
28806116
25.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
26.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ, Hellmann MD.

PLoS One. 2017 Aug 3;12(8):e0182665. doi: 10.1371/journal.pone.0182665. eCollection 2017.

27.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

28.

Investigation of patterns of nodal metastases in BRAF mutant lung cancer.

McEvoy SH, Halpenny DF, Viteri-Jusué A, Hayes SA, Plodkowski AJ, Riely GJ, Ginsberg MS.

Lung Cancer. 2017 Jun;108:62-65. doi: 10.1016/j.lungcan.2017.02.024. Epub 2017 Mar 1.

29.

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Patel SH, Rimner A, Foster A, Zhang Z, Woo KM, Yu HA, Riely GJ, Wu AJ.

Lung Cancer. 2017 Jun;108:109-114. doi: 10.1016/j.lungcan.2017.03.010. Epub 2017 Mar 24.

30.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

31.

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2017 Apr;15(4):504-535.

PMID:
28404761
32.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

33.

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Socinski MA, Chaft JE, Levy B, Riely GJ, Langer CJ, Perez-Soler R, Middleton DL, Gracie-King L, Healy LM.

Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5. No abstract available.

PMID:
28188100
34.

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

Dagogo-Jack I, Shaw AT, Riely GJ.

Clin Pharmacol Ther. 2017 May;101(5):625-633. doi: 10.1002/cpt.653. Epub 2017 Mar 17. Review.

PMID:
28182271
35.

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Lin JJ, Riely GJ, Shaw AT.

Cancer Discov. 2017 Feb;7(2):137-155. doi: 10.1158/2159-8290.CD-16-1123. Epub 2017 Jan 25. Review.

36.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ.

Ann Oncol. 2017 Feb 1;28(2):278-284. doi: 10.1093/annonc/mdw556.

37.

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.

Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J, Yan S, Wei G, Oliver JW, Patel R, Multani P, Ladanyi M, Drilon A.

Clin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23.

38.

Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Arbour KC, Riely GJ.

Hematol Oncol Clin North Am. 2017 Feb;31(1):101-111. doi: 10.1016/j.hoc.2016.08.012. Review.

39.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A.

J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. Review. No abstract available.

40.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

41.

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.

Yu HA, Perez L, Chang Q, Gao SP, Kris MG, Riely GJ, Bromberg J.

J Thorac Oncol. 2017 Jan;12(1):102-109. doi: 10.1016/j.jtho.2016.08.140. Epub 2016 Sep 6.

42.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Jul;14(7):825-36.

PMID:
27407123
43.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM.

J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9. Review.

45.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.

Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7.

46.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.

Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.

47.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.

PMID:
26957612
48.

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC.

Clin Lung Cancer. 2016 Sep;17(5):e121-e129. doi: 10.1016/j.cllc.2016.01.003. Epub 2016 Jan 21.

49.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators.

Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Erratum in: Lancet Oncol. 2017 Mar;18(3):e134.

50.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

Supplemental Content

Loading ...
Support Center